Jonathan Stein

In this 45-minute discussion, we will examine pioneering strategies for redefining functional outcomes in aging interventions, emphasizing rapid, impactful markers of rejuvenation and aging. We will cover hurdles in integrating advanced technologies and standardized performance metrics into clinical trials, alongside navigating complex regulatory landscapes to validate QoL measures:

Using short-term recovery (i.e. post-surgery strength gains) as meaningful early indicators

Integrating wearables and physical performance tests into clinical trial design

Building regulatory acceptance for quality-of-life metrics over mortality

• The overlap between cancer and biological models of aging
• Inelegant (but effective) problem solving bypassing the blood-brain barrier and treating the untreatable
• Coordinating diagnostic and therapeutic strategies to manage Leptomeningeal Metastases (LM)